Literature DB >> 25066050

Low prevalence of human immunodeficiency virus and hepatitis C virus co-infection in a medium size city in southern Brazil.

Carina Sperotto Librelotto1, Daniel Simon2, Nilo Ikuta1, Vagner Ricardo Lunge1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25066050      PMCID: PMC9425223          DOI: 10.1016/j.bjid.2014.05.014

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   3.257


× No keyword cloud information.
Dear Editor, Approximately 35.3 million of people are infected with the human immunodeficiency virus (HIV) worldwide, and 20–30% of them are also contaminated with the hepatitis C virus (HCV). The introduction of highly active antiretroviral therapy increased the survival time and improved the quality of life of HIV-infected individuals, however hepatic diseases related to chronic HCV infection became the main cause of morbidity and mortality in these patients. The present work aimed to study the prevalence and risk factors for HCV infection in a sample of HIV-infected patients from a medium size urban center in the countryside of South Brazil. Adult individuals with HIV receiving care in a reference outpatient treatment center for HIV testing and AIDS treatment in Cruz Alta (located in the Northwest region of the state of Rio Grande do Sul, Brazil) were consecutively enrolled in the study from July 2011 to August 2012. Socio-demographic and potential risk factors for HIV infection were obtained with a standardized individual questionnaire. General laboratory and clinical data were obtained from the medical records. All participants signed an informed consent form. The study was approved by the Research Ethics Committees of the Universidade Luterana do Brasil. A total of 148 HIV-infected patients were included in the study. Sixteen patients (10.8%) had anti-HCV and HCV-RNA positive results. A total of 13 patients (81.2%) were infected with HCV genotype 1, and three (18.8%) with genotype 3. Use of intravenous drugs and report of possible HIV acquisition by sharing needles were significantly higher in co-infected than in mono-infected patients (p < 0.001) (Table 1). The time period since HIV diagnosis was longer in co-infected than in mono-infected patients (p = 0.041). A higher proportion of HIV/HCV co-infected patients (100.0%) than mono-infected patients (62.1%) had undergone surgery in the past (p = 0.008). In the multivariate analysis, use of injecting drugs (p = 0.021), surgery history (p < 0.001) and male gender (p < 0.001) were the independent risk factors associated with HIV/HCV co-infection.
Table 1

Distribution of socio-demographic and epidemiological characteristics in HIV-positive patients according to HCV status.

VariableTotal(n = 148)HCV-negative(n = 132)HCV-positive(n = 16)p
Male gender67 (45.2)58 (43.9)9 (56.3)0.428
Age (years)41.9 ± 11.941.9 ± 12.241.6 ± 8.70.898



Education level0.829
 Complete primary education or less109 (73.6)97 (73.5)12 (75.0)
 Secondary or higher education39 (26.3)35 (26.5)4 (25.0)



Sexual orientationa0.947
 Heterosexual136 (91.8)120 (90.9)16 (100.0)
 Homosexual6 (4.0)6 (4.5)
 Bisexual5 (3.3)5 (3.8)



Possible forms of HIV infectiona,b
 Sex127 (85.8)112 (84.8)15 (93.8)0.577
 Blood transfusion7 (4.7)6 (4.5)1 (6.3)0.931
 Cutting objects2 (1.3)2 (1.5)0.878
 Sharing needles5 (3.3)1 (0.8)4 (25.0)<0.001



Time since HIV diagnosis (years)a6.1 ± 5.65.7 ± 5.48.9 ± 6.10.041
Number of sexual partners in the past 12 monthsa1.8 ± 2.41.8 ± 2.42.1 ± 2.20.654
Use of condom during last occurrence of sexual intercourse90 (60.8)78 (59.1)12 (75.0)0.894
Injecting drug use4 (2.7)4 (25.0)<0.001
Smoking drug use22 (14.8)19 (14.4)3 (18.8)0.823
Snorting drug use24 (16.2)19 (14.4)5 (31.3)0.511
Blood transfusion38 (25.6)33 (25.0)5 (31.3)0.910
Tattoo43 (29.0)35 (26.5)8 (50.0)0.120
Piercing10 (6.7)7 (5.3)3 (18.8)0.123
Surgery98 (66.2)82 (62.1)16 (100.0)0.008
Endoscopy34 (22.9)32 (24.2)2 (12.5)0.941
Sharing toothbrushes19 (12.8)17 (12.9)2 (12.5)0.928
Sharing sharp objects (in salon, manicure, pedicure, barber and personal care)61 (41.2)57 (43.2)4 (25.0)0.187
Working in the health service11 (7.4)9 (6.8)2 (12.5)0.686
STD history46 (31.0)38 (28.8)8 (50.0)0.265
HAART use111 (75.0)99 (75.0)12 (75.0)0.847

Note: Variables expressed as number (percentage) or mean ± standard deviation.

STD, sex transmitted disease; HAART, highly active antiretroviral therapy.

Bold values are those statistically significant (p<0.05), but this emphasis can be omitted.

Totals do not coincide due to lack of data from certain participants in the study.

Multiple response.

Distribution of socio-demographic and epidemiological characteristics in HIV-positive patients according to HCV status. Note: Variables expressed as number (percentage) or mean ± standard deviation. STD, sex transmitted disease; HAART, highly active antiretroviral therapy. Bold values are those statistically significant (p<0.05), but this emphasis can be omitted. Totals do not coincide due to lack of data from certain participants in the study. Multiple response. The prevalence of HIV/HCV co-infection varies with the geographic region. In Brazil, reports estimated an average of 20.3% of HIV/HCV co-infection, ranging from 3.3% to 82.4% according to the region. Epidemiological studies conducted in the capital cities and metropolitan regions from Brazil have demonstrated high HIV/HCV co-infection, mainly associated to injecting drug use. However, epidemiological reports are sparse from the countryside, limiting a better understanding of these epidemiological aspects in Brazil. The present study focused in the city of Cruz Alta, a medium size urban center with one of the highest incidence rate of HIV/AIDS in Rio Grande do Sul. HIV/HCV co-infection frequency was lower than in the two cities of the metropolitan area of the state, Porto Alegre (31.2%) and Canoas (23.8%).4, 5 Interestingly the frequency of injecting drug users was also lower in the investigated population (2.7%) than those reported in other studies.4, 5 The low HIV/HCV co-infection prevalence is probably related to the low frequency of injecting drug users in the community. This epidemiologic knowledge is essential for the development of specific prevention strategies in small and medium size cities from the Brazilian countryside.

Conflicts of interest

The authors declare no conflicts of interest.
  4 in total

Review 1.  HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Authors:  Eva A Operskalski; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

2.  Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates.

Authors:  Fernando H Wolff; Sandra C Fuchs; Nêmora N T Barcellos; Paulo Ricardo de Alencastro; Maria Letícia R Ikeda; Ajácio B M Brandão; Maicon Falavigna; Flávio D Fuchs
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

3.  Alcohol misuse and illicit drug use are associated with HCV/HIV co-infection.

Authors:  D Simon; R T Michita; J U Béria; D C Tietzmann; A T Stein; V R Lunge
Journal:  Epidemiol Infect       Date:  2014-02-04       Impact factor: 4.434

Review 4.  Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: a review.

Authors:  Valdete Meurer Kuehlkamp; Fabiana Schuelter-Trevisol
Journal:  Braz J Infect Dis       Date:  2013-05-13       Impact factor: 3.257

  4 in total
  2 in total

Review 1.  HIV and Substance Use in Latin America: A Scoping Review.

Authors:  Hanalise V Huff; Paloma M Carcamo; Monica M Diaz; Jamie L Conklin; Justina Salvatierra; Rocio Aponte; Patricia J Garcia
Journal:  Int J Environ Res Public Health       Date:  2022-06-12       Impact factor: 4.614

Review 2.  Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review.

Authors:  Fatima Mitiko Tengan; Karim Yakub Ibrahim; Bianca Peixoto Dantas; Caroline Manchiero; Mariana Cavalheiro Magri; Wanderley Marques Bernardo
Journal:  BMC Infect Dis       Date:  2016-11-09       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.